Kishima Haruhiko, Yanagisawa Takufumi, Goto Yuko, Oshino Satoru, Maruo Tomoyuki, Tani Naoki, Khoo Hui Ming, Hosomi Koichi, Hirata Masayuki, Yoshimine Toshiki
Department of Neurosurgery, Osaka University Graduate School of Medicine, Suita, Japan.
Department of Neuromodulation and Neurosurgery, Osaka University Graduate School of Medicine, Suita, Japan.
Neuromodulation. 2016 Aug;19(6):650-4. doi: 10.1111/ner.12394. Epub 2016 Feb 2.
Intrathecal baclofen (ITB) therapy is an effective treatment for patients with severe spasticity. However, the effect of ITB therapy on respiratory function has not been reported in detail. In this study we quantitatively analyzed the effects of ITB on the respiratory function of patients with spastic tetraplegia.
We retrospectively reviewed 23 patients who were administrated ITB therapy from January 2009 to December 2012. Six of these 23 patients, who had spastic tetraplegia and were able to undergo spirometric testing, were included this study. The spasticity derived from cervical spinal cord injury in four patients and cerebral palsy (CP) in two patients. Patients' Ashworth Scale scores and spirometer measurements obtained before and 1-6 months after the start of ITB therapy were evaluated and compared.
Before ITB therapy, %FVC of all six patients was below 80%, and a restrictive respiratory disorder was diagnosed in five patients and a combined respiratory disorder in one patient. Ashworth Scale scores for both the lower and upper extremities improved significantly with ITB therapy. Forced vital capacity (FVC), %FVC, and forced expiratory volume at one sec also improved significantly with ITB therapy.
Respiratory disorders were indeed present in our SCI and CP patients with spastic tetraplegia, and the respiratory function of these patients improved with ITB therapy. Our results suggest that ITB therapy is safe and efficacious in patients with spastic tetraplegia and respiratory dysfunction.
鞘内注射巴氯芬(ITB)疗法是治疗严重痉挛患者的有效方法。然而,ITB疗法对呼吸功能的影响尚未有详细报道。在本研究中,我们定量分析了ITB对痉挛性四肢瘫患者呼吸功能的影响。
我们回顾性分析了2009年1月至2012年12月接受ITB治疗的23例患者。这23例患者中有6例患有痉挛性四肢瘫且能够进行肺功能测试,被纳入本研究。其中4例患者的痉挛源于颈脊髓损伤,2例源于脑瘫(CP)。评估并比较了患者在ITB治疗开始前以及开始后1 - 6个月的Ashworth量表评分和肺功能仪测量结果。
在ITB治疗前,所有6例患者的%FVC均低于80%,5例被诊断为限制性呼吸障碍,1例为混合性呼吸障碍。ITB治疗后,上下肢的Ashworth量表评分均显著改善。用力肺活量(FVC)、%FVC和1秒用力呼气量也因ITB治疗而显著改善。
我们的脊髓损伤和脑瘫痉挛性四肢瘫患者确实存在呼吸障碍,且这些患者的呼吸功能通过ITB治疗得到改善。我们的结果表明,ITB疗法对痉挛性四肢瘫和呼吸功能障碍患者是安全有效的。